Pfizer (PFE) Inventory (2009 - 2026)

Pfizer has disclosed Inventory across 18 years of filings, most recently posting $10.7 billion for Q1 2026.

• In Q1 2026, Inventory fell 1.7% year-over-year to $10.7 billion; the TTM figure through Mar 2026 stood at $10.7 billion (down 1.7% YoY), while the FY2025 annual figure was $10.7 billion, down 1.82% from the prior year.
• Inventory held at $10.7 billion in Q1 2026, from $10.7 billion in the prior quarter.
• Over the last five years, Inventory for PFE reached as high as $11.7 billion in Q3 2024 and fell as low as $9.0 billion in Q4 2022.
• The 5-year median for Inventory is $10.7 billion (2025), against an average of $10.6 billion.
• Annual changes were most pronounced in 2022 — Inventory climbed 17.5% — and 2023, when it declined 4.39%.
• A 5-year view of Inventory shows it stood at $9.0 billion in 2022, then gained by 13.45% to $10.2 billion in 2023, then climbed by 6.5% to $10.9 billion in 2024, then retreated by 1.82% to $10.7 billion in 2025, then advanced by 0.12% to $10.7 billion in 2026.
• According to Business Quant data, Inventory over the past three periods registered $10.7 billion, $10.7 billion, and $11.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.